Abstract
Prostate cancer, the second most common cancer among male adults, affects millions globally. We sought to investigate the expression and contribution of Eukaryotic translation initiation factor 3 subunit b (EIF3B) in prostate cancer. Expression of EIF3B was analyzed in both human prostate patient tissues and prostate cancer cell lines. Small interfering RNA (siRNA) knockdown of EIF3B was introduced into prostate cancer cell line PC-3 and LNCaP, followed by examination of cell viability, proliferation and apoptosis using the MTT, cell counting and terminal deoxynucleotidyl transferase dUTP nick end labeling assays, respectively. An in vivo xenograft tumor mouse model was employed to address the role of EIF3B in tumorigenesis as well. Finally, a gene microarray analysis was performed to search for differentially expressed genes upon EIF3B knockdown. EIF3B was upregulated in prostate tumor tissues and prostate cancer cell lines. EIF3B knockdown inhibited viability and proliferation of prostate cancer cells, as well as promoted cell apoptosis. In the in vivo mouse model, inoculation of EIF3B knockdown PC-3 cells displayed inhibited growth of xenograft tumors. In addition, potential signaling pathways that might be involved in EIF3B action in prostate cancer were identified by the gene microarray. EIF3B is a novel oncogenic factor in prostate cancer both in vitro and in vivo, which could be employed as a novel therapeutic target in the treatment against prostate cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aslan M, Shahbazi R, Ulubayram K, Ozpolat B (2018) Targeted therapies for pancreatic cancer and hurdles ahead. Anticancer Res 38:6591–6606. https://doi.org/10.21873/anticanres.13026
Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B (2004) Human prostate cancer risk factors. Cancer 101:2371–2490. https://doi.org/10.1002/cncr.20408
Carvalho A, Chu J, Meinguet C, Kiss R, Vandenbussche G, Masereel B, Wouters J, Kornienko A, Pelletier J, Mathieu V (2017) A harmine-derived beta-carboline displays anti-cancer effects in vitro by targeting protein synthesis. Eur J Pharmacol 805:25–35. https://doi.org/10.1016/j.ejphar.2017.03.034
Chai RC, Wang N, Chang YZ, Zhang KN, Li JJ, Niu JJ, Wu F, Liu YQ, Wang YZ (2019) Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma. Cancer Cell Int 19:155. https://doi.org/10.1186/s12935-019-0867-1
Chaudhuri J, Chakrabarti A, Maitra U (1997) Biochemical characterization of mammalian translation initiation factor 3 (eIF3). Molecular cloning reveals that p110 subunit is the mammalian homologue of Saccharomyces cerevisiae protein Prt1. J Biol Chem 272:30975–30983. https://doi.org/10.1074/jbc.272.49.30975
Choi YJ, Lee YS, Lee HW, Shim DM, Seo SW (2017) Silencing of translation initiation factor eIF3b promotes apoptosis in osteosarcoma cells. Bone Joint Res 6:186–193. https://doi.org/10.1302/2046-3758.63.BJR-2016-0151.R2
Cusan M, Mungo G, De Marco ZM, Segatto I, Belletti B, Baldassarre G (2018) Landscape of CDKN1B mutations in luminal breast cancer and other hormone-driven human tumors. Front Endocrinol (Lausanne) 9:393. https://doi.org/10.3389/fendo.2018.00393
Falletta P, Sanchez-Del-Campo L, Chauhan J, Effern M, Kenyon A, Kershaw CJ, Siddaway R, Lisle R, Freter R, Daniels MJ, Lu X, Tuting T, Middleton M, Buffa FM, Willis AE, Pavitt G, Ronai ZA, Sauka-Spengler T, Holzel M, Goding CR (2017) Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. Genes Dev 31:18–33. https://doi.org/10.1101/gad.290940.116
Fukuchi-Shimogori T, Ishii I, Kashiwagi K, Mashiba H, Ekimoto H, Igarashi K (1997) Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res 57:5041–5044
Garcia G, Odaimi M (2017) Systemic combination chemotherapy in elderly pancreatic cancer: a review. J Gastrointest Cancer 48:121–128. https://doi.org/10.1007/s12029-017-9930-0
Grosso S, Volta V, Sala LA, Vietri M, Marchisio PC, Ron D, Biffo S (2008) PKCbetaII modulates translation independently from mTOR and through RACK1. Biochem J 415:77–85. https://doi.org/10.1042/BJ20080463
Joyce CE, Yanez AG, Mori A, Yoda A, Carroll JS, Novina CD (2017) Differential regulation of the melanoma proteome by eIF4A1 and eIF4E. Cancer Res 77:613–622. https://doi.org/10.1158/0008-5472.CAN-16-1298
Liang H, Ding X, Zhou C, Zhang Y, Xu M, Zhang C, Xu L (2012) Knockdown of eukaryotic translation initiation factors 3B (EIF3B) inhibits proliferation and promotes apoptosis in glioblastoma cells. Neurol Sci 33:1057–1062. https://doi.org/10.1007/s10072-011-0894-8
Masutani M, Sonenberg N, Yokoyama S, Imataka H (2007) Reconstitution reveals the functional core of mammalian eIF3. EMBO J 26:3373–3383. https://doi.org/10.1038/sj.emboj.7601765
Pernar CH, Ebot EM, Wilson KM, Mucci LA (2018) The epidemiology of prostate cancer. Cold Spring Harbor Perspect Med. https://doi.org/10.1101/cshperspect.a030361
Qu Y, Zhao R, Wang H, Chang K, Yang X, Zhou X, Dai B, Zhu Y, Shi G, Zhang H, Ye D (2016) Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp.112 translocation renal cell carcinoma. Sci Rep 6:23594. https://doi.org/10.1038/srep23594
Reiss K, Del Valle L, Lassak A, Trojanek J (2012) Nuclear IRS-1 and cancer. J Cell Physiol 227:2992–3000. https://doi.org/10.1002/jcp.24019
Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. JAMA 294:238–244. https://doi.org/10.1001/jama.294.2.238
Shen MM, Abate-Shen C (2010) Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 24:1967–2000. https://doi.org/10.1101/gad.1965810
Tian Y, Zhao K, Yuan L, Li J, Feng S, Feng Y, Fang Z, Li H, Deng R (2018) EIF3B correlates with advanced disease stages and poor prognosis, and it promotes proliferation and inhibits apoptosis in non-small cell lung cancer. Cancer Biomark 23:291–300. https://doi.org/10.3233/CBM-181628
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644–648. https://doi.org/10.1126/science.1117679
Truitt ML, Conn CS, Shi Z, Pang X, Tokuyasu T, Coady AM, Seo Y, Barna M, Ruggero D (2015) Differential requirements for eIF4E dose in normal development and cancer. Cell 162:59–71. https://doi.org/10.1016/j.cell.2015.05.049
van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, Caldas C, Schreiber KE, Hardwick RH, Ausems MG, Bardram L, Benusiglio PR, Bisseling TM, Blair V, Bleiker E, Boussioutas A, Cats A, Coit D, DeGregorio L, Figueiredo J, Ford JM, Heijkoop E, Hermens R, Humar B, Kaurah P, Keller G, Lai J, Ligtenberg MJ, O'Donovan M, Oliveira C, Pinheiro H, Ragunath K, Rasenberg E, Richardson S, Roviello F, Schackert H, Seruca R, Taylor A, Ter Huurne A, Tischkowitz M, Joe ST, van Dijck B, van Grieken NC, van Hillegersberg R, van Sandick JW, Vehof R, van Krieken JH, Fitzgerald RC (2015) Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 52:361–374. https://doi.org/10.1136/jmedgenet-2015-103094
Vaysse C, Philippe C, Martineau Y, Quelen C, Hieblot C, Renaud C, Nicaise Y, Desquesnes A, Pannese M, Filleron T, Escourrou G, Lawson M, Rintoul RC, Delisle MB, Pyronnet S, Brousset P, Prats H, Touriol C (2015) Key contribution of eIF4H-mediated translational control in tumor promotion. Oncotarget 6:39924–39940. https://doi.org/10.18632/oncotarget.5442
Wang H, Ru Y, Sanchez-Carbayo M, Wang X, Kieft JS, Theodorescu D (2013) Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization. Clin Cancer Res 19:2850–2860. https://doi.org/10.1158/1078-0432.CCR-12-3084
Wang L, Ouyang L (2019) Effects of EIF3B gene downregulation on apoptosis and proliferation of human ovarian cancer SKOV3 and HO-8910 cells. Biomed Pharmacother 109:831–837. https://doi.org/10.1016/j.biopha.2018.10.027
Wang Z, Chen J, Sun J, Cui Z, Wu H (2012) RNA interference-mediated silencing of eukaryotic translation initiation factor 3, subunit B (EIF3B) gene expression inhibits proliferation of colon cancer cells. World J Surg Oncol 10:119. https://doi.org/10.1186/1477-7819-10-119
Wolfe AL, Singh K, Zhong Y, Drewe P, Rajasekhar VK, Sanghvi VR, Mavrakis KJ, Jiang M, Roderick JE, Van der Meulen J, Schatz JH, Rodrigo CM, Zhao C, Rondou P, de Stanchina E, Teruya-Feldstein J, Kelliher MA, Speleman F, Porco JA Jr, Pelletier J, Ratsch G, Wendel HG (2014) RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature 513:65–70. https://doi.org/10.1038/nature13485
Xu F, Xu CZ, Gu J, Liu X, Liu R, Huang E, Yuan Y, Zhao G, Jiang J, Xu C, Chu Y, Lu C, Ge D (2016) Eukaryotic translation initiation factor 3B accelerates the progression of esophageal squamous cell carcinoma by activating beta-catenin signaling pathway. Oncotarget 7:43401–43411. https://doi.org/10.18632/oncotarget.9726
Zang Y, Zhang X, Yan L, Gu G, Li D, Zhang Y, Fang L, Fu S, Ren J, Xu Z (2017) Eukaryotic translation initiation factor 3b is both a promising prognostic biomarker and a potential therapeutic target for patients with clear cell renal cell carcinoma. J Cancer 8:3049–3061. https://doi.org/10.7150/jca.19594
Acknowledgements
Not applicable.
Funding
The study was supported by the internal departmental funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Research involving Human Participants
Studies involving human participants obtained the official approval from the Ethic Committee of the First Affiliated Hospital of University of Science and Technology of China and were conducted in strict conformity with the Declaration of Helsinki Principles.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Xiang, P., Sun, Y., Fang, Z. et al. Eukaryotic translation initiation factor 3 subunit b is a novel oncogenic factor in prostate cancer. Mamm Genome 31, 197–204 (2020). https://doi.org/10.1007/s00335-020-09842-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00335-020-09842-4